SCPH (scpharmaceuticals.com) Net Profit

Corporate emblem and logo of scPharmaceuticals Inc. (SCPH)

scPharmaceuticals Inc. (SCPH) business is shielded from external political risks, as it focuses exclusively on the US domestic market. The company develops innovative subcutaneous drug delivery methods for heart patients, which reduces hospitalization and justifies premium pricing power. The price history on GURU.Markets reflects the asset's dynamics, where the current figure is -0.09.

SCPH (scpharmaceuticals.com) Company Net Income history from 07/04/2022 to 10/18/2025

Financial and market metric breakdowns for scpharmaceuticals.com (SCPH)

- price and consensus price forecast:
Stock Quotes scPharmaceuticals|SCPH - Analyst Consensus Forecast
- business market valuation indicators:
Market Capitalization scPharmaceuticals Inc.|SCPH - Real Price to Acquire Entire Company
- book capitalization data:
Accounting Value of a Share scPharmaceuticals|SCPH - Company Book Value|Market-to-Book Ratio scpharmaceuticals.com|SCPH - Cumulative Company Assets
- debt and solvency information:
Aggregate Debt to Capital scPharmaceuticals Inc.|SCPH - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital scPharmaceuticals|SCPH - Company Aggregate Debts|Debts to Book Value scPharmaceuticals Inc.|SCPH - Company Long-Term Debt|Company Short-Term Loans and Borrowings scPharmaceuticals|Interim Coverage Ratio scpharmaceuticals.com
- net income and valuation multiples indicators:
SCPH - Net Profit
Fundamental valuation:SCPH scPharma
Flagship merchandise of scPharmaceuticals, Inc.

scPharmaceuticals Inc. (SCPH) focuses on implementing home treatment systems for heart failure. The company's profit dynamics reflect the difference between operating income from commercialization and development costs. This indicator measures the actual rate of cash generation, excluding market speculation. A declining line amid rising quotes signals a risk of asset overvaluation. Analyzing this metric allows for a sober assessment of the business's long-term sustainability.

Main competitors

Net Income Haleon Corp|KVUE (Kenvue Inc.) - Net Profit|Net Profit veronapharma.com|Net Income MENS (Jyong Biotech)|LGND (Ligand Pharmaceuticals Incorporated) - Final Profit|Company Net Income Amneal Pharmaceuticals Inc AMRX|Perrigo Corp (PRGO) - Company Net Income|ALVO: Net Income|liquidia.com - Profit After Payment of Taxes|GLPG: Net Profit|ANI Pharmaceuticals Inc - Final Profit|MNKD (MannKind Corp.) - Net Profit|Company Net Income Amphastar Corp AMPH|Company Net Income Pacira BioSciences (PCRX)|SPRY (ars-pharma.com) - Final Profit|Company Net Income Theravance Biopharma, Inc. TBPH|Net Financial Result Aquestive Therapeutics Inc (AQST)|Tectonic - Net Profit|Tonix Pharmaceuticals Holding (TNXP) - Net Income|sxtchina.com (SXTC) - Company Net Income|Profit After Tax EPRX (Eupraxia Pharmaceuticals Inc.)|BHST (BioHarvest Sciences Inc.) - Net Profit|EXOZ: Final Profit|Net Profit ORMP|Net Profit enterabio.com (ENTX)|Company Net Income MindWalk Holdings HYFT|Final Profit ABVC|CPIX - Company Net Income|Quantum BioPharma Ltd. (QNTM) - Net Income|FGEN: Net Profit|Telomir Pharmaceuticals Corp (TELO) - Net Profit|RANI (Rani Therapeutics Holdings) - Net Profit|Net Income Synergy CHC Corporation (SNYR)|Net Profit RLYB|LEXX - Company Net Income|Pulmatrix Corp - Net Income|Net Profit Pheton Holdings Limited PTHL|APM: Net Income|lyratherapeutics.com - Profit After Payment of Taxes|IBO: Net Profit|TNFA - Net Financial Result|YCBD (cbdMD Inc.) - Net Profit|Net Income PainReform Corp (PRFX)|Net Profit CYTO|Net Profit lipella.com (LIPO)|Company Net Income OptiNose OPTN|Pieris Pharmaceuticals Inc - Company Net Income|PROC - Company Net Income|Net Financial Result Petros Pharma PTPI|QLI (Qilian International) - Net Income|acelyrin.com - Final Profit|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit